Holen Sie sich die Stockscreener-App
151.62
0.30%
0.45
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$151.17
Offen:
$151.835
24-Stunden-Volumen:
697.96K
Relative Volume:
0.14
Marktkapitalisierung:
$188.00B
Einnahmen:
$29.79B
Nettoeinkommen (Verlust:
$9.22B
KGV:
20.63
EPS:
7.3494
Netto-Cashflow:
$10.23B
1W Leistung:
+4.83%
1M Leistung:
+5.50%
6M Leistung:
+9.09%
1J Leistung:
+29.39%
1-Tages-Spanne:
$150.84
$152.26
1-Wochen-Bereich:
$142.60
$151.44
52-Wochen-Spanne:
$114.02
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
151.62 | 188.00B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,184.43 | 1.06T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
262.22 | 631.92B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
278.16 | 491.54B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
145.74 | 359.57B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
143.81 | 273.34B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-07-21 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-07-06 | Hochstufung | HSBC Securities | Hold → Buy |
| 2026-05-20 | Hochstufung | Maxim Group | Hold → Buy |
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? - The Motley Fool
RBC raises target for Gilead Sciences stock to USD 126.00 - AD HOC NEWS
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings - Zacks Investment Research
Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD) - Yahoo! Finance Canada
Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD) - Yahoo Finance
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
Cantor Fitzgerald Reaffirms Overweight Rating for Gilead Sciences (NASDAQ:GILD) - MarketBeat
Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD) - TradingView
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Truist Financial Analyst Says - MarketBeat
Gilead Sciences (NASDAQ:GILD) Stock Gets Price Target Boost from JPMorgan Chase & Co. - MarketBeat
U.S. Stocks Slip Ahead of Fed Minutes; Gilead Sciences (GILD) Ga - GuruFocus
Gilead Sciences (NASDAQ:GILD) Stock Price Target Cut by Morgan Stanley - MarketBeat
Gilead Sciences Is Maintained at Overweight by Morgan Stanley - Moomoo
Gilead Sciences stock gains 2.57 percent after AI agreement expands - AD HOC NEWS
Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX) - Benzinga
JPMorgan Adjusts Price Target on Gilead Sciences to $170 From $160 - marketscreener.com
Gilead Sciences signs five-year DevOps agreement with Cognizant - Pharmaceutical Technology
Gilead Sciences signs five-year DevOps agreement with Cognizant - Yahoo Finance
Cognizant Expands AI-Enabled DevOps Capabilities for Gilead Sciences - PR Newswire
Drugmaker Gilead gets AI support for selected tech programs under a five-year extension - Stock Titan
12,110 Gilead Sciences, Inc. $GILD Shares Sold by CapWealth Advisors LLC - MarketBeat
Gilead Sciences (NASDAQ:GILD) Offers Dividend Investors Quality Income and Valuation Support - ChartMill
Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP - The Motley Fool
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know - Zacks Investment Research
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
Under a prearranged trading plan, Gilead Sciences (GILD) CEO sells 15,000 shares. - Stock Titan
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
Confluence Investment Management LLC Cuts Position in Gilead Sciences, Inc. $GILD - MarketBeat
More Upside Awaits for Gilead Sciences Stock. Stay Invested. - Barron's
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Zacks Investment Research
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors - Zacks Investment Research
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors - Yahoo Finance
Gilead Sciences stock reports growth at EUR 133.42, plus 0.02 percent - AD HOC NEWS
Gilead Sciences (NASDAQ:GILD) Stock: Stronger HIV Sales Meet Weaker Reported Earnings - kalkine.ca
Can Lenacapavir Power Gilead Sciences (GILD)’s Next Growth Phase? - finance.yahoo.com
Gilead vs. Intuitive Surgical: Which Healthcare Stock Offers the Better Risk-Adjusted Upside? - Yahoo Finance
Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing? - finance.yahoo.com
Can Gilead Sciences (GILD) Justify Its Price As It Raises 2026 Guidance And Dividend? - Yahoo Finance
CEUX:GISd Dividend: Does Gilead Sciences Inc Pay a Dividend? - GuruFocus
Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward? - finance.yahoo.com
Gilead or Johnson & Johnson: Is Faster Growth Better than Greater Diversification? - Yahoo Finance
Gilead Sciences, Inc. (NASDAQ:GILD) Stock Has Average Price Target of $158.78 According to Analysts - MarketBeat
Gilead Sciences, Inc. $GILD Stake Decreased by Envestnet Asset Management Inc. - MarketBeat
Gilead Sciences Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Gilead Sciences stock slips 0.85 percent ahead of the open - AD HOC NEWS
Gilead: HIV Growth Is Not Enough At The Current Price (NASDAQ:GILD) - Seeking Alpha
Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH - The Motley Fool
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Gilead Sciences Inc-Aktie (GILD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Dickinson Andrew D | Chief Financial Officer |
Sep 15 '26 |
Sale |
145.29 |
3,000 |
435,870 |
164,096 |
| ANDREW DICKINSON | Officer |
Sep 15 '26 |
Proposed Sale |
145.29 |
3,000 |
435,870 |
0 |
| JOHANNA MERCIER | Officer |
Sep 15 '26 |
Proposed Sale |
144.22 |
3,000 |
432,646 |
0 |
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Sep 15 '26 |
Sale |
144.22 |
3,000 |
432,646 |
116,684 |
| O'Day Daniel Patrick | Chairman & CEO |
Sep 01 '26 |
Sale |
148.64 |
15,000 |
2,229,592 |
577,133 |
| WELTERS ANTHONY | Director |
Aug 26 '26 |
Option Exercise |
61.06 |
18,000 |
1,099,052 |
23,176 |
| ANTHONY WELTERS | Director |
Aug 26 '26 |
Proposed Sale |
148.77 |
18,000 |
2,677,860 |
0 |
| WELTERS ANTHONY | Director |
Aug 26 '26 |
Sale |
148.62 |
18,000 |
2,675,220 |
12,894 |
| Bluestone Jeffrey | Director |
Aug 20 '26 |
Sale |
145.02 |
5,000 |
725,078 |
10,066 |
| Bluestone Jeffrey | Director |
Aug 20 '26 |
Option Exercise |
67.04 |
5,000 |
335,207 |
11,882 |
0.55%
0.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):